NeuPath Health Inc. · TSXV:NPTH

NeuPath Health — Investor Presentation (April 2021)

20 slides from NeuPath Health's investor presentation, April 2021

  1. Slide 1: Corporate Presentation April 2021

    CORPORATE PRESENTATION APRIL 2021 TSXV: NPTH www.neupath.com

  2. Slide 2: Legal Disclaimer

    Legal Disclaimer Certain statements contained in this Presentation may constitute forward-looking information under the meaning of applicable securities laws, which are based on the opinions, estimates and assumptions of the NeuPath’s management and are subject to a variety of risks, uncertainties a

  3. Slide 3: Legal Disclaimer – non-IFRS Measures

    Legal Disclaimer – non-IFRS Measures Non-IFRS Measures This presentation contains financial terms (such as adjusted EBITDA) that are not considered in IFRS. Such financial measures, together with measures prepared in accordance with IFRS, provide useful information to investors and shareholders, as

  4. Slide 4: NeuPath Health overview

    NeuPath Health overview $57M NeuPath owns and operates a network of 13 140,000+ Annual clinics across Canada that 13 wholly- annual Revenue Run deliver category-leading owned clinics patient visits Rate1 treatment for chronic pain, as well as spinal injuries, sports related injuries, and concussions

  5. Slide 5: Investment highlights

    Investment highlights • Largest pain & musculoskeletal clinic network in Canada • 13 wholly owned clinics plus minority interests in 2 more clinics • Blended care model, combining in-person & virtual visits • Proprietary remote pain management tech & virtual visits comprise 9% of total visits • Annu

  6. Slide 6: Positive EBITDA & access to capital = platform for growth

    Positive EBITDA & access to capital = platform for growth aa aa aa aa aa May 2017 Feb 2018 Jul 2020 Oct 2020 Nov 2020 Feb 2021 Mar 2021 • NeuPath • Acquired • Started • Began work • Closed • Expanded to • Reported 8th was founded group of 3 trading on with Pivot to oversubscribed Alberta consecutive

  7. Slide 7: $37 billion+ total addressable market

    $37 billion+ total addressable market • NeuPath is focused on treating musculoskeletal pain and related conditions • Chronic Pain • $15-$17 billion annual direct health care costs in Canada2 • Sport Medicine • Injuries cost public health system $1.5 billion annually3 • Concussions • $1 billion annua

  8. Slide 8: Research, Technology, Interdisciplinary Care

    Research Technology Interdisciplinary Care • Evidence-based care is our • Technology to enhance care • Collaborative care model starting point • Improve outcomes • Roster includes: • Leverage our wholly-owned • Improve scalability and • Physiatrists Contract Research reach • Neurologists Organizatio

  9. Slide 9: Comprehensive, holistic service offering

    Comprehensive, holistic service offering • Comprehensive assessments • Ultrasound guided injections 70% to • Physiotherapy • Electromyography No physician physician & • Psychotherapy • Non-imaging guided payment or not 30% to • Chronic Pain Self- injections monetized company Management Program • Med

  10. Slide 10: Remote pain management technology

    Remote pain management technology • Musculoskeletal conditions are the biggest cost driver in organizations’ health care spending in Canada & US • Chronic pain is the leading cause of disability & disease burden globally • NeuPath is developing proprietary digital health tech targeting musculoskelet

  11. Slide 11: Remote pain management technology

    Remote pain management technology • Personalized education on the impact of sleep, diet, exercise, medication, and other contributing factors • Access to coaching • Self-management tools • Enhanced tracking and measurement of changes in patient function • Improved communication with care providers •

  12. Slide 12: Growth strategy

    Growth strategy • Increase capacity utilization from 53% in existing clinics • Add services, onboard new doctors, and improve patient throughput • Continue to build out national network by acquiring and building new clinics • National network is critical to rollout of employer health program • Relea

  13. Slide 13: Financial Performance and Capitalization

    Financial Performance and Capitalization Growing Adjusted EBITDA Margins HealthPointe Acquisition Impact through the Pandemic • $9M - 2020 revenue • 6% - 2020 Adjusted EBITDA margin • 64% - Capacity Utilization during COVID Capitalization • 45.1M - Shares Outstanding • 70.9M – Fully Diluted • 11.4%

  14. Slide 14: Comparable Companies

    Comparable Companies Share Market Cap EV CAGR - Revenue EV / Sales Company Price (C$mm, as of 2021-04-19) 1 Year 2 Year 3 Year CY19 CY20 CY21e 1Life Healthcare (NASDAQ: ONEM) US$ 40.92 6,884.9 6,511.1 53.1% 30.8% n.d. 18.8x 13.7x 10.8x WELL Health (TSX: WELL) C$ 7.16 1,391.5 1,510.4 76.5% 118.1% n.m

  15. Slide 15: Experienced Leadership Team

    Experienced Leadership Team • Joined in July 2018 • Former CEO of VroomHealth Grant Connelly • Former CFO of Appletree Medical Group that operated over 30 medical clinics Chief Executive Officer • Over $200M in M&A transactions • MBA – Schulich School of Business at York • Joined in April 2019 • CPA

  16. Slide 16: Board of Directors

    Board of Directors Dianne Carmichael, Chair Jolyon Burton • Former President, Best Doctors Inc. • Co-founder of Bloom Burton & Co., providing capital raising, • Former President, Payer Markets at McKesson M&A advisory, equity research, business strategy & scientific • Former President, UHN Solutions

  17. Slide 17: Investment highlights

    Investment highlights • Largest pain & musculoskeletal clinic network in Canada • 13 wholly owned clinics plus minority interests in 2 more clinics • Blended care model, combining in-person & virtual visits • Proprietary remote pain management tech & virtual visits comprise 9% of total visits • Annu

  18. Slide 18: Thank You

    NeuPath Health Grant Connelly, CEO gconnelly@neupath.com Thank You Stephen Lemieux, CFO slemieux@neupath.com investors@neupath.com 18

  19. Slide 19: Corporate Presentation

    CORPORATE PRESENTATION APRIL 2021 TSXV: NPTH www.neupath.com

  20. Slide 20: Adjusted EBITDA

    Adjusted EBITDA Non-IFRS Measures EBITDA refers to net income (loss) determined in accordance with IFRS, before depreciation and amortization, net interest expense (income) and income tax expense (recovery). The Company defines adjusted EBITDA as net income from continuing operations before net inte

NeuPath Health — Investor Presentation (April 2021) on 6ix